Positive Health Online
Your Country
Super Patch – Quantum Innovation
by Rima Laibow MD and Clare G Harvey(more info)
listed in energy medicine, originally published in issue 294 - May 2024
In 2021, David Julius and Ardem Patapoutian were honoured with the Nobel Prize in Physiology or Medicine for uncovering the existence of thermal and mechanical sensors within the skin. Their groundbreaking work revealed that our skin is equipped with receptors sensitive to touch, pressure, vibrations, and temperature changes. These receptors communicate vital information to the brain, enabling it to react, safeguard the body, and either pursue further interaction or retreat from the source of stimulation. The pressure sensors they discovered facilitate a dialogue with the brain through both the peripheral and central nervous systems, offering essential biofeedback.
https://en.wikipedia.org/wiki/2021_Nobel_Prize_in_Physiology_or_Medicine
The Nobel Assembly at Karolinska Institutet awarded the 2021 Nobel Prize in Physiology or Medicine jointly to David Julius and Ardem Patapoutian for their discoveries of
receptors for temperature and touch
Haptic Vibrotactile Trigger Technology (VTT) is advancing the field of sensory feedback by creating immersive and detailed experiences, particularly in pain management and sensory augmentation. This technology leverages vibrotactile stimuli to interact with the human sensory system, modulating experiences ranging from pain reduction to enhanced perception of virtual environments. Research demonstrates its potential to disrupt traditional pain treatment methods and develop novel sensory devices that could mimic real-life textures or provide sensory feedback for prosthetics and virtual reality applications. When applied directly to the skin, the patch serves as a form of biofeedback, engaging in communication with the brain.
https://www.superpatch.com/how-the-tech-works
Vibrotactile feedback applies vibrations to stimulate a user's skin,
Once the Super Patch is in contact with your skin, it triggers a response in the brain's
neural networks that helps you tackle your daily problems, head-on.
The Super Patch company is at the forefront of this innovative field, leveraging its patented technology. What sets Super Patch apart is its commitment to conducting clinical studies on its products, with additional research planned for the future. This article will explore the Freedom Pain Patch study in detail.
A recent study, Haptic Vibrotactile Trigger Technology: Disrupting the Neuromatrix to Reduce Pain Severity and Interference: Results from the HARMONI on VTT technology, conducted by Jeffrey Gudin, Derek Dietze, Galen Dhaliwal, and Peter Hurwitz, discusses pain reduction, severity, and interference.[1] The study evaluated the effectiveness of a non-invasive, non-pharmacological pain patch embedded with VTT in adult patients with musculoskeletal, arthritic, and neurological pain. The results showed statistically significant decreases in pain severity and interference scores after using the VTT-embedded pain patch. Patients also reported reduced usage of oral medications and high satisfaction with the patch. The study suggests that the non-pharmacological topical pain patch has the potential to be an effective addition to non-invasive and non-pharmacological pain therapies.
The Most Important Takeaway Points of the Study:
- The HARMONI study evaluated the effectiveness of a haptic vibrotactile trigger technology (VTT) embedded non-pharmacologic, non-invasive pain patch in reducing pain severity and interference in patients with musculoskeletal, arthritic, and neurological pain.
- The study included 148 adult subjects with a mean age of 53 years who presented with mild, moderate, and severe pain. The patients wore the VTT embedded pain patch for 14 days, and their pain severity and interference scores were measured using the Brief Pain Inventory (BPI) scale.
- The results showed statistically significant decreases in mean BPI severity and interference scores after using the VTT-embedded pain patch. The majority of patients reported “less” or “a lot less” usage of oral medications and were very/extremely satisfied with the patch. There were also positive outcomes in various quality-of-life components.
- The VTT technology targets the nociceptive pathways and disrupts the neuromatrix of pain, which is a network of neuronal pathways and circuits responding to sensory stimulation. The technology has been incorporated into non-invasive, non-pharmacological topical patches.
- The study suggests that the non-pharmacological topical pain patch embedded with VTT technology has the potential to be an effective addition to non-invasive and non-pharmacological pain therapies.
https://en.wikipedia.org/wiki/File:Melzack_Ronald.jpg
Dr Ronald Melzack OC OQ FRSC photographed in the library of the senior citizens residence where
he resided; he died in 2019. Dr Melzack proposed the neuromatrix theory of pain, 1968.
https://firsthand.com/paperz/Melzack2001.pdf
What is the Neuromatrix of Pain?
The neuromatrix of pain is a network of neuronal pathways and circuits that respond to sensory (nociceptive) stimulation. It is a widely distributed neural network in the brain that generates characteristic patterns of nerve impulses, known as “neurosignature” patterns, in response to pain. These patterns are responsible for the multidimensional experience of pain and can be triggered by various inputs, including tactile sensations. The neuromatrix theory of pain suggests that pain is not solely caused by tissue injury or damage but rather is a complex experience produced by specific patterns of neural activity within this network. The neuro matrix includes regions such as the somatosensory cortex, insular cortex, anterior and posterior cingulate cortices, prefrontal cortex, and thalamus. It is involved in the perception, modulation, and interpretation of pain signals, as well as the cognitive, emotional, and motor aspects of pain. Understanding the neuromatrix of pain has important implications for developing non-pharmacological and non-invasive pain therapies that target these neural pathways and circuits to reduce pain severity and interference.
What Percentage of Patients Reported Less Usage of Oral Medications after 14 Days?
82% of patients reported “less” or “a lot less” usage of oral medications after 14 days.
What is the Primary Pain Complaint of the Patients in the Study?
The primary pain complaint for the patients in the study is musculoskeletal pain, specifically myofascial/musculoskeletal pain, which was indicated by 36.5% of the patients (54 out of 148).
What Kind of Pain does the VTT Embedded Pain Patch Target?
The VTT-embedded pain patch is specifically designed to target arthritic, neuropathic, and musculoskeletal pain. This innovative patch offers a non-pharmacologic, non-invasive, haptic vibrotactile trigger technology (VTT) embedded topical patch that reduces pain severity and interference scores with daily activities. In addition, it may reduce the use of concurrent medications, including prescribed anti-inflammatory and other oral medication for adult patients with arthritic, neuropathic, and musculoskeletal pain according to the study.
The Results of the Treatment Group in the Study Showed the Following
Pain Severity and Interference Scores: There was a statistically significant decrease in mean Brief Pain Inventory – BPI severity and interference scores after using the VTT embedded pain patch. The mean BPI severity score decreased from 4.02 at baseline to 2.15 at day 14. The mean BPI interference score decreased from 2.59 at baseline to 1.29 at day 14. Use of Concurrent Medications: After 14 days, the vast majority of patients reported “less” or “a lot less” usage of oral medications for pain relief. Specifically, 82% of patients reported using less oral medications.
Patient Satisfaction: The majority of patients (75%) were satisfied with the treatment, and of those, 83% were very/extremely satisfied with the patch.
Quality of Life (QoL) Improvements: The study showed statistically significant and positive outcomes in all measured Quality of Life components. Patients reported improvements in general activity, mood, relations with other people, sleep, normal work, walking ability, and enjoyment of life.
Duration of Pain Relief: Approximately 10% of patients reported that their pain did not return after removing the patch, and 44% of patients reported that it took longer than one day for the pain to return after patch removal.
Safety: There was only one reported adverse event (swelling) deemed as non-serious by the treating clinician. No other adverse skin reactions or serious adverse events were reported.
Overall, the results suggest that the non-pharmacologic, non-invasive, haptic vibrotactile trigger technology (VTT) embedded topical patch reduces pain severity and interference scores, improves quality of life, and may reduce the use of concurrent medications for adult patients with arthritic, neuropathic, and musculoskeletal pain.
Conclusion
The results of the HARMONI study indicate that the haptic vibrotactile trigger technology (VTT) embedded topical patch, known as the FREEDOM Super Patch, is a non-pharmacologic and non-invasive treatment option that reduces pain severity and interference scores in adult patients with arthritic, neuropathic, and musculoskeletal pain. The study also suggests that the use of this patch may lead to a reduction in the use of concurrent medications, including prescribed anti-inflammatory and other oral medications. Patients reported high levels of satisfaction with the patch and improvements in various aspects of their quality of life. The study findings support the potential of the VTT embedded pain patch as an effective addition to the current array of non-invasive and non-pharmacological pain therapies. Further research, including control and crossover group data, will provide additional evidence to support the use of this patch as a first-line treatment option in a multimodal approach to pain management.
This heralds the start of a groundbreaking frequency technology in Quantum innovation, with which we will next be showcasing Sleep/REM and other more advanced solutions to re: educated and recalibrate the original function of the brain patterns that are ultimately responsible for balance, homeostasis and overall smooth functions of our body as a whole.
Further Information
For more info and product please see link https://shop.superpatch.com/#/shop/from/111165003
Reference
- Gudin, J., Dietze, D., Dhaliwal, G., & Hurwitz, P. (2022). Haptic Vibrotactile Trigger Technology: Disrupting the Neuromatrix to Reduce Pain Severity and Interference: Results from the HARMONI Study. Anesthesia & Pain Research. https://doi.org/10.33425/2639-846x.1070 https://www.scivisionpub.com/pdfs/haptic-vibrotactile-trigger-technology-disrupting-the-neuromatrix-to-reduce-pain-severity-and-interference-results-from-the-harmon-2564.pdf
Comments:
-
No Article Comments available